Eledon Pharmaceuticals, Inc.
Datakwaliteit: 83%
ELDN
Nasdaq
Manufacturing
Chemicals
€ 3,10
€ 0,00
(0,00%)
Marktkapitalisatie: 248,44 M
Prijs
€ 3,12
Marktkapitalisatie
248,44 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Negative free cash flow of -62,34 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-106,46%
Onder sectorgemiddelde (-53,34%)
ROICN/A
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio6,74
Interest CoverageN/A
Waardering
PE (TTM)
-5,45
Onder sectorgemiddelde (-1,47)
P/B Ratio7,03
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -5,5 | -1,5 |
| P/B | 7,0 | 1,6 |
| ROE % | -106,5 | -53,3 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -45,62 M |
| ROE | -106,46% | ROA | -33,20% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -62,34 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 6,74 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 82,01 M | Tangible Book Value | 35,36 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -5,45 | Forward P/E | N/A |
| P/B Ratio | 7,03 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -25,09% | ||
| Market Cap | 248,44 M | Enterprise Value | 244,77 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,52 | Revenue / Share | N/A |
| FCF / Share | -0,78 | OCF / Share | -0,78 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 136,66% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -45,62 M | -36,18 M | -40,33 M | -87,97 M | -34,51 M |
| EPS (Diluted) | -0,52 | -0,75 | -1,64 | -6,16 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | -43,00 M | -88,43 M | -36,87 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 66,27 M | 51,96 M | 30,31 M | 27,08 M | 23,74 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | 5.000,0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 35.000,0 | 431.000,0 | 0,0 | 0,0 | -2,35 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 169,01 M | 177,41 M | 89,07 M | 92,79 M | 170,55 M |
| Total Liabilities | 32,23 M | 59,27 M | 5,65 M | 8,61 M | 6,55 M |
| Shareholders' Equity | 81,09 M | 118,14 M | 83,42 M | 84,18 M | 164,00 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 22,81 M | 20,55 M | 4,61 M | 56,41 M | 84,83 M |
| Current Assets | 135,69 M | 143,73 M | 56,13 M | 59,52 M | 88,35 M |
| Current Liabilities | 18,34 M | 11,58 M | 3,90 M | 6,48 M | 4,40 M |
{"event":"ticker_viewed","properties":{"ticker":"ELDN","listing_kind":"stock","pathname":"/stocks/eldn","exchange":"Nasdaq","country":"US"}}